About NGM Biopharmaceuticals
NGM Biopharmaceuticals is a company based in San Francisco (United States) founded in 2007. NGM Biopharmaceuticals has raised $358.87 million across 8 funding rounds from investors including Merck, The Column Group and Prospect Venture Partners. NGM Biopharmaceuticals offers products and services including NGM120 and Pipeline Drugs. NGM Biopharmaceuticals operates in a competitive market with competitors including Rhythm Pharmaceuticals, MannKind Corp, Nimbus Therapeutics, Corcept and Altimmune, among others.
- Headquarter San Francisco, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ngm Biopharmaceuticals, Inc.
-
Annual Revenue
$4.42 M (USD)-92.26as on Dec 31, 2023
-
Net Profit
-$142.53 M (USD)15.13as on Dec 31, 2023
-
EBITDA
-$144.49 M (USD)12.68as on Dec 31, 2023
-
Total Equity Funding
$358.87 M (USD)
in 8 rounds
-
Latest Funding Round
$142.04 M (USD), Post-IPO
Jul 05, 2024
-
Investors
Merck
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of NGM Biopharmaceuticals
NGM Biopharmaceuticals is a publicly listed company on the GETTEX with ticker symbol 0IK in Germany, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of NGM Biopharmaceuticals
NGM Biopharmaceuticals offers a comprehensive portfolio of products and services, including NGM120 and Pipeline Drugs.
Drug candidate for treating Hyperemesis Gravidarum in clinical trials
In-house developed drugs addressing various global diseases
People of NGM Biopharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of NGM Biopharmaceuticals
NGM Biopharmaceuticals has successfully raised a total of $358.87M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $142.04 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NGM Biopharmaceuticals
NGM Biopharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, The Column Group and Prospect Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in US life sciences and healthtech firms.
|
Locked | Locked | Locked | |
|
Early-stage investments in US life science startups are focused on.
|
Locked | Locked | Locked | |
|
Topspin Consumer Partners is engaged in private equity investments focused on consumer brands.
|
Locked | Locked | Locked |
Investor details for NGM Biopharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NGM Biopharmaceuticals
Investment portfolio details for NGM Biopharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NGM Biopharmaceuticals
Detailed financials for NGM Biopharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ngm Biopharmaceuticals Comparisons
Peer comparison for NGM Biopharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NGM Biopharmaceuticals
NGM Biopharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rhythm Pharmaceuticals, MannKind Corp, Nimbus Therapeutics, Corcept and Altimmune, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of cortisol modulators for the treatment of various diseases
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
Detailed competitors of NGM Biopharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ngm Biopharmaceuticals
Complete news archive for NGM Biopharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NGM Biopharmaceuticals
NGM Biopharmaceuticals was founded in 2007 and raised its 1st funding round 1 year after it was founded.
NGM Biopharmaceuticals is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
David J Woodhouse is the current CEO of NGM Biopharmaceuticals.
NGM Biopharmaceuticals is a funded company, having raised a total of $358.87M across 8 funding rounds to date.
Annual revenue of NGM Biopharmaceuticals is $4.42M as on Dec 31, 2023.
NGM Biopharmaceuticals was founded in 2007 and is based in San Francisco, United States. Biologics are developed in the biopharmaceutical sector for treating cardio-metabolic and liver diseases. Operations focus on drug candidates such as NGM282, which targets bile acid-related conditions and non-alcoholic steatohepatitis. Additional candidates address Type 2 diabetes and obesity. Leadership is provided by CEO David J. Woodhouse.
NGM Biopharmaceuticals's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
NGM Biopharmaceuticals offers NGM120 and Pipeline Drugs.
Yes, NGM Biopharmaceuticals is publicly traded on GETTEX under the ticker symbol 0IK.
NGM Biopharmaceuticals has 6 investors. Key investors include Merck, The Column Group, Prospect Venture Partners, Topspin Consumer Partners, and Tichenor Ventures.
The ticker symbol of NGM Biopharmaceuticals is 0IK on GETTEX.